Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world evaluation of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer
ISRCTN52513758Phase 4Completed
- Sponsor
- Urology Department, ASL 2 Abruzzo
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Urology Department, ASL 2 Abruzzo. Primary endpoint: Progression-free survival / overall survival measure as defined by protocol. Started Nov 2015; status: completed.
02
Drugs
abirateroneprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ISRCTN52513758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52513758.